Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 243.1% in January

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,536,000 shares, a growth of 243.1% from the January 15th total of 447,700 shares. Based on an average trading volume of 2,008,300 shares, the short-interest ratio is currently 0.8 days.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY traded up $0.07 during trading on Wednesday, hitting $5.54. The company had a trading volume of 648,213 shares, compared to its average volume of 1,169,202. The firm has a market capitalization of $21.77 billion, a price-to-earnings ratio of -21.31 and a beta of 1.04. The stock has a fifty day simple moving average of $5.23 and a two-hundred day simple moving average of $6.44. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. Bayer Aktiengesellschaft has a fifty-two week low of $4.79 and a fifty-two week high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Tuesday, November 12th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The firm had revenue of $10.96 billion for the quarter. On average, research analysts expect that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.